Skip to main content
. Author manuscript; available in PMC: 2011 Nov 4.
Published in final edited form as: Eur J Immunol. 2010 Jul;40(7):1985–1994. doi: 10.1002/eji.200940282

Figure 1. CTLA4-Ig promotes the resolution of airway inflammation in BTLA−/− mice.

Figure 1

C57BL/6 or BTLA−/− deficient mice were sensitized and challenged with OVA. Groups of mice (n=5/group) received either control or CTLA4-Ig (100 μg, ip) on either day 1 and day 7 or on day 3 only following challenge. Samples were collected for analysis 10 days following the inhaled challenge. A) Schematic representation of the experimental protocol. B) Representative lung sections stained with H&E. C) Total BAL cell numbers and D) differential analysis of cells recovered from the BAL fluid. Data show mean + SD (n=5) and are representative of more than 5 independent experiments, **p<0.01, ***p<0.0005, ****p<0.0001 as compared to BTLA−/− mice that had not received CTLA4-Ig.